Which is the original pharmaceutical company of Sorafenib/Nexavar?

Sorafenib (Sorafenib), the international general trade name is Nexavar (Nexavar), is an oral targeted anti-tumor drug jointly developed by the German pharmaceutical giant Bayer AG and the American biotechnology company Onyx Pharmaceuticals. This drug is one of the first targeted drugs in the world to be successfully used in the treatment of liver cancer. Its launch marks a key step in the field of molecular targeted therapy in the treatment of solid tumors. Bayer is a well-known pharmaceutical and life science company in the world, with its business covering prescription drugs, over-the-counter drugs, crop science and other sectors. Onyx has certain forward-looking technologies and research platforms in the development of targeted drugs. Sorafenib, jointly developed by the two companies, eventually became a "milestone" drug in the field of liver cancer treatment.

In In 2005, sorafenib was first approved by the US FDA for the treatment of advanced renal cell carcinoma, and then in 2007, it was approved for the treatment of advanced hepatocellular carcinoma, and then gradually expanded to other indications such as differentiated thyroid cancer that is ineffective in radioactive iodine therapy. This multi-target small molecule drug achieves the effect of inhibiting tumor growth and angiogenesis by simultaneously inhibiting Raf kinase in tumor cells and signaling pathways such as VEGFR and PDGFR in the tumor microenvironment. As an original research company, Bayer has long held the global production and distribution rights of sorafenib, especially in the European, North American and Asian markets. It is relatively standardized in terms of clinical application, drug quality control and after-sales support, so original drugs still have a high priority in doctors' recommendations.

Although in recent years, with the expiration of sorafenib patents, various generic versions have appeared on the market, including multiple domestic and foreign manufacturers, Bayer's original drug is still the first choice for many patients due to its long-term clinically proven efficacy, safety data and regulatory quality.

Reference materials:https://www.nexavar.com/